A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma

F1000Research

Volumn 4, Issue , 2017, Pages

  Modiano, Jaime ^a,b,e   Ito, Daisuke ^a,b   Childress, Michael ^c   Mason, Nicola ^d   Winter, Amber ^a   O'Brien, Timothy ^a,b,e   Henson, Michael ^a,b   Borgatti, Antonella ^a,b   Lewellen, Mitzi ^a,b   Krick, Erika ^d   Stewart, Jane ^c   Lahrman, Sarah ^c   Rajwa, Bartek ^c   Scott, Milcah C ^a,b   Seelig, Davis ^a,b   Koopmeiners, Joseph ^a,b,f   Ruetz, Stephan ^g  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c PURDUE UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ABCB1 P glycoprotein; Canine; Cells; Lymphoma; Non Hodgkin; Progenitor; Valspodar

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD34 ANTIGEN; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; STEM CELL FACTOR RECEPTOR; VALSPODAR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; BEAGLE; BLOOD SAMPLING; BULLDOG; CANCER REGRESSION; CANCER STAGING; CELL COUNT; CONTROLLED STUDY; DOG BREED; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GOLDEN RETRIEVER; HISTOPATHOLOGY; LABRADOR RETRIEVER; LYMPHOID PROGENITOR CELL; MALE; NEOADJUVANT THERAPY; NONHUMAN; OVERALL SURVIVAL; PILOT STUDY; POODLE (DOG); PROTEIN EXPRESSION; SPRINGER SPANIEL (DOG); TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 85017178149     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.6055.2     Document Type: Article

References (60)

1. Nguyen LV Vanner R Dirks P: Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12(2):133-43. 22237392 10.1038/nrc3184
2. Lee CG Das B Lin TL: A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential. Br J Haematol. 2012;158(1):79-90. 22509798 10.1111/j.1365-2141.2012.09123.x 3374069
3. Lee MR Ju HJ Kim BS: Isolation of side population cells in B-cell non-Hodgkin's lymphomas. Acta Haematol. 2013;129(1):10-7. 22964907 10.1159/000341284
4. Vega F Davuluri Y Cho-Vega JH: Side population of a murine mantle cell lymphoma model contains tumour-initiating cells responsible for lymphoma maintenance and dissemination. J Cell Mol Med. 2010;14(6B):1532-45. 19656242 10.1111/j.1582-4934.2009.00865.x 3829019
5. Wang Y Liu Y Malek SN: Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell. 2011;8(4):399-411. 21474104 10.1016/j.stem.2011.02.006 3084595
6. Ito D Endicott MM Jubala CM: A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma. J Vet Intern Med. 2011;25(4):890-6. 21777289 10.1111/j.1939-1676.2011.0756.x 4993164
7. Ito D Frantz AM Modiano JF: Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet Immunol Immunopathol. 2014;159(3-4):192-201. 24642290 10.1016/j.vetimm.2014.02.016 4994713
8. Donnenberg VS Donnenberg AD: Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005;45(8):872-7. 16027397 10.1177/0091270005276905
9. Gottesman MM Fojo T Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48-58. 11902585 10.1038/nrc706
10. Ueda K Cardarelli C Gottesman MM: Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987;84(9):3004-8. 3472246 10.1073/pnas.84.9.3004 304789
11. Frantz AM Sarver AL Ito D: Molecular profiling reveals prognostically significant subtypes of canine lymphoma. Vet Pathol. 2013;50(4):693-703. 23125145 10.1177/0300985812465325 4683027
12. Nobili S Landini I Giglioni B: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006;7(7):861-79. 16842217 10.2174/138945006777709593
13. Tai HL: Technology evaluation: Valspodar, Novartis AG. Curr Opin Mol Ther. 2000;2(4):459-67. 11249778
14. Cagliero E Ferracini R Morello E: Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. Oncol Rep. 2004;12(5):1023-31. 15492788 10.3892/or.12.5.1023
15. Minami H Ohtsu T Fujii H: Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance. Jpn J Cancer Res. 2001;92(2):220-30. 11223552 10.1111/j.1349-7006.2001.tb01085.x
16. Sonneveld P Marie JP Huisman C: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia. 1996;10(11):1741-50. 8892677
17. Friedenberg WR Rue M Blood EA: Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006;106(4):830-8. 16419071 10.1002/cncr.21666
18. Lhommé C Joly F Walker JL: Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008;26(16):2674-82. 18509179 10.1200/JCO.2007.14.9807
19. Kolitz JE George SL Marcucci G: P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116(9):1413-21. 20522709 10.1182/blood-2009-07-229492 2938834
20. Ito D Brewer S Modiano JF: Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leuk Lymphoma. 2015;56(1):219-225. 24724777 10.3109/10428194.2014.914193 5002357
21. Ito D Frantz AM Williams C: CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma. 2012;53(7):1390-8. 22229753 10.3109/10428194.2011.654337 3727651
22. Gorden BH Kim JH Sarver AL: Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. Am J Pathol. 2014;184(4):985-95. 24525151 10.1016/j.ajpath.2013.12.025 3969990
23. Valli VE San Myint M Barthel A: Classification of canine malignant lymphomas according to the World Health Organization criteria. Vet Pathol. 2011;48(1):198-211. 20861499 10.1177/0300985810379428
24. Mealey KL: Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther. 2004;27(5):257-64. 15500562 10.1111/j.1365-2885.2004.00607.x
25. Mealey KL Bentjen SA Gay JM: Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics. 2001;11(8):727-33. 11692082 10.1097/00008571-200111000-00012
26. Chan AW Tetzlaff JM Altman DG: SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-7. 23295957 10.7326/0003-4819-158-3-201302050-00583 5114123
27. Jubala CM Wojcieszyn JW Valli VE: CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet Pathol. 2005;42(4):468-76. 16006606 10.1354/vp.42-4-468
28. Vail DM: Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol. 2004;2(4):195-213. 19379294 10.1111/j.1476-5810.2004.0053b.x
29. Khammanivong A Gorden BH Frantz AM: Identification of drug-resistant subpopulations in canine hemangiosarcoma. Vet Comp Oncol. 2014. 25112808 10.1111/vco.12114
30. Gorden BH Saha J Khammanivong A: Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression. Vasc Cell. 2014;6:20. 25295160 10.1186/2045-824X-6-20 4188569
31. Bolger AM Lohse M Usadel B: Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114-20. 24695404 10.1093/bioinformatics/btu170 4103590
32. Kim D Langmead B Salzberg SL: HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12(4):357-60. 25751142 10.1038/nmeth.3317 4655817
33. Li H Handsaker B Wysoker A: The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-19. 19505943 10.1093/bioinformatics/btp352 2723002
34. Trapnell C Roberts A Goff L: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562-78. 22383036 10.1038/nprot.2012.016 3334321
35. Vail DM Michels GM Khanna C: Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol. 2010;8(1):28-37. 20230579 10.1111/j.1476-5829.2009.00200.x
36. Chun R: Lymphoma: which chemotherapy protocol and why? Top Companion Anim Med. 2009;24(3):157-62. 19732735 10.1053/j.tcam.2009.03.003
37. Binkhathlan Z Somayaji V Brocks DR: Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;869(1-2):31-7. 18514043 10.1016/j.jchromb.2008.05.003
38. Modiano JF Breen M Avery AC: Breed Specific Canine Lymphoproliferative Diseases. In: Ostrander EA, Giger U, Lindblad-Toh K editors. The Dog and its Genome.Cold Spring Harbor: CSH Press;2005. Reference Source
39. Modiano JF Breen M Burnett RC: Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 2005;65(13):5654-61. 15994938 10.1158/0008-5472.CAN-04-4613
40. Tan B Piwnica-Worms D Ratner L: Multidrug resistance transporters and modulation. Curr Opin Oncol. 2000;12(5):450-8. 10975553 10.1097/00001622-200009000-00011
41. Modok S Mellor HR Callaghan R: Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 2006;6(4):350-4. 16690355 10.1016/j.coph.2006.01.009
42. Rodriguez C Commes T Robert J: Expression of P-glycoprotein and anionic glutathione S-transferase genes in non-Hodgkin's lymphoma. Leuk Res. 1993;17(2):149-56. 8094105 10.1016/0145-2126(93)90060-X
43. Zandvliet M Teske E Schrickx JA: Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression, a potential model for drug-resistant canine lymphoma. Toxicol In Vitro. 2014;28(8):1498-506. 24975508 10.1016/j.tiv.2014.06.004
44. Kim MC D'Costa S Suter S: Evaluation of a side population of canine lymphoma cells using Hoechst 33342 dye. J Vet Sci. 2013;14(4):481-6. 23820219 10.4142/jvs.2013.14.4.481 3885743
45. Idriss HT Hannun YA Boulpaep E: Regulation of volume-activated chloride channels by P-glycoprotein: phosphorylation has the final say! J Physiol. 2000;524(Pt 3):629-36. 10790147 10.1111/j.1469-7793.2000.00629.x 2269906
46. Bernt KM Armstrong SA: Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):33-8. 19100366 10.1053/j.seminhematol.2008.09.010 4031465
47. Moti N Malcolm T Hamoudi R: Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. Oncogene. 2015;34(14):1843-52. 24814516 10.1038/onc.2014.112
48. Lohr JG Stojanov P Lawrence MS: Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012;109(10):3879-84. 22343534 10.1073/pnas.1121343109 3309757
49. Lund K Adams PD Copland M: EZH2 in normal and malignant hematopoiesis. Leukemia. 2014;28(1):44-9. 24097338 10.1038/leu.2013.288
50. Velichutina I Shaknovich R Geng H: EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 2010;116(24):5247-55. 20736451 10.1182/blood-2010-04-280149 3012542
51. Zhang Y Liu G Lin C: Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Life Sci. 2013;92(17-19):896-902. 23562851 10.1016/j.lfs.2013.03.010
52. Tang B Zhang Y Liang R: RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy. Oncol Rep. 2013;29(3):1037-42. 23291714 10.3892/or.2013.2222
53. Mudaliar MA Haggart RD Miele G: Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL). PLoS One. 2013;8(9):e72591. 24023754 10.1371/journal.pone.0072591 3762807
54. Richards KL Motsinger-Reif AA Chen HW: Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res. 2013;73(16):5029-39. 23783577 10.1158/0008-5472.CAN-12-3546 3755352
55. Bardelmeijer HA Ouwehand M Beijnen JH: Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs. 2004;22(3):219-29. 15122069 10.1023/B:DRUG.0000026248.45084.21
56. Binkhathlan Z Hamdy DA Brocks DR: Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat. Xenobiotica. 2010;40(1):55-61. 19903013 10.3109/00498250903331056
57. Smith AJ Mayer U Schinkel AH: Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst. 1998;90(15):1161-6. 9701366 10.1093/jnci/90.15.1161
58. Ghetie MA Crank M Kufert S: Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J Immunother. 2006;29(5):536-44. 16971809 10.1097/01.cji.0000211307.05869.6c
59. Ghetie MA Marches R Kufert S: An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood. 2004;104(1):178-83. 15001473 10.1182/blood-2003-12-4255
60. Ito D Childress MO Mason NJ: Data of pilot study on valspodar in neoadjuvant settings for canine B-cell lymphoma. F1000Research. 2015. Data Source